Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04103853
Other study ID # GT0918-CN-2001
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 6, 2017
Est. completion date June 30, 2020

Study information

Verified date September 2021
Source Suzhou Kintor Pharmaceutical Inc,
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a multi-center, open-label, dose-esclation I/Ib clinical study to explore safety, efficacy an pharmacokinetics of proxalutamide in patients with metastatic breast cancer. This study includes two stages, stage I: single- and multiple-dose tolerance and pharmacokinetic study; stage 2: preliminary efficacy and safety study.


Description:

This study is a multi-center, open-label, dose-esclation study. Subjects will be enrolled to the 100mg, 200mg, 300mg, 400mg and 500mg group in turn. Unless DLT was found, the dose esclation will continue. 28 days of DLT observation period is needed after 7-day single dose administration, until disease progression, intolerable toxicities (AEs), or withdrawn consent. After the completion of stage 1, 2 doses for the stage 2 will be determined. In stage 2, patients with AR-positive metastatic breast cancer will be selected to explore the efficacy and safety of proxalutamide, and biomarkers will be explored.


Recruitment information / eligibility

Status Completed
Enrollment 63
Est. completion date June 30, 2020
Est. primary completion date May 22, 2019
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age =18 years female; 2. Stage 1:Histology or cytology confirmed metastatic breast cancer, first-line chemotherapy or targeted therapy failure or intolerance Stage 2: Histological or cytological confirmed metastatic breast cancer patients who failed or intolerant to anti-tumor therapy; have a positive AR test result; 3. At least one measurable lesion based on RECIST version 1.1 ; 4. ECOG performance status: 0-1; 5. Have a predicted life expectancy of greater than 3 months; 6. The functions of the important organs are confirmed with the following requirement: - Hemoglobin (HGB) = 90 g/L(no blood transfusion within 14 days ); - Absolute neutrophil count (ANC) = 1.5×10^9/L; - Platelets (PLT) = 100×10^9/L(If the coagulation function is normal,Platelets (PLT) = 75×10^9/L ); - Total bilirubin (TBIL) = 1.5× Upper limit of normal value (ULN) -Aspartate aminotransferase (AST), alkaline phosphatase (ALP), and alanine - - Aminotransferase (ALT) =2.5× ULN 7. Understand and voluntarily sign the informed consent form; 8. Subject is willing and able to comply with all protocol required visits and assessments; Exclusion Criteria: 1. Pregnant, lactating women, or those who have fertility and are reluctant to take effective contraceptive measures; 2. Prior chemotherapy, radiation, targeted therapy ,androgen receptor inhibitors therapy (abiraterone,enzalutamide,etc ),other endocrine therapy ,and has acceptted traditional chinese herbal medicine treatment less than 4 weeks prior to the start of study medication. 3. Has severe cardiovascular disease 4. The toxicity of the previous treatment plan has not been restored before enrollment, and there is still non-hematologic toxicity of grade 1 or above (except for hair loss) 5. Known gastrointestinal disease or condition that affects the absorption of GT0918; 6. Known or suspected brain metastases, including the central nervous system and spinal cord compression or meningeal metastasis; 7. History of severe central nervous system diseases (including patients with epilepsy); 8. Known hypersensitivity to proxalutmide or its excipients. 9. Participated in clinical trials of other drugs or medical devices within one month prior to screening, or plan to participate in any other clinical trials during the study period; 10. Subjects with any other serious disease considered by the investigator not in the condition to enter into the trial;

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Proxalutamide
Stage1:Dose esclation. Stage2:the expansion cohort where one or no DLT takes place in planned study cohort.

Locations

Country Name City State
China Beijing Cancer Hospital Beijing Beijing
China Hunan Cancer Hospital Changsha Hunan
China Sun-Yat-sen University Cancer center Guangzhou Fujian
China Jiangsu Province Hospital Nanjing Jiangsu
China Ruijin Hospital, Shanghai Jiaotong University School of Medicine Shanghai Shanghai
China The Fourth Hospital of Hebei Medical University Shijiazhuang Hebei
China Tianjin Medical University Cancer Institute and Hospital Tianjin Tianjin

Sponsors (8)

Lead Sponsor Collaborator
Suzhou Kintor Pharmaceutical Inc, Beijing Cancer Hospital, Hebei Medical University Fourth Hospital, Hunan Cancer Hospital, Ruijin Hospital, Sun Yat-sen University, The First Affiliated Hospital with Nanjing Medical University, Tianjin Medical University Cancer Institute and Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose-limiting Toxicity(DLT) Each dose cohort will initially include 3 evaluable patients for assessment of toxicity within the 35 days following the first dose of GT0918. 35 days
Primary maximum tolerated dose (MTD) 100 mg, 200 mg, 300 mg, 400 mg or 500 mg of GT0918 35 days
Primary Disease Control Rate(DCR) Preliminary evaluation of the DCR of GT0918 tablets in AR positive metastatic breast cancer patients, and determination of the recommended dose of proclamine in clinical trials. 16 weeks
Secondary maximum concentration (Cmax) Pharmacokinetics 35 days
Secondary time that maximum concentration is observed (tmax) Pharmacokinetics 35 days
Secondary area under the concentration time-curve from time zero to infinity (AUC08) Pharmacokinetics 35 days
Secondary terminal elimination half life (t½) Pharmacokinetics 35 days
Secondary drug clearance (CL) Pharmacokinetics 35 days
Secondary apparent volume of distribution (Vd) Pharmacokinetics 35 days
Secondary Number of participants with treatment-related adverse events as assessed by CTCAE V4.03 200 mg, 300 mg of GT0918 16 weeks
See also
  Status Clinical Trial Phase
Withdrawn NCT04872608 - A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer Phase 1
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Completed NCT02506556 - Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer Phase 2
Recruiting NCT05534438 - A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer Phase 2
Recruiting NCT03368729 - Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer Phase 1/Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Active, not recruiting NCT03147287 - Palbociclib After CDK and Endocrine Therapy (PACE) Phase 2
Not yet recruiting NCT06062498 - Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer Phase 2
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Recruiting NCT04095390 - A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer Phase 2
Active, not recruiting NCT04432454 - Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Phase 2
Recruiting NCT03323346 - Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer Phase 2
Recruiting NCT05744375 - Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab Phase 2
Completed NCT02924883 - A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy Phase 2
Completed NCT01881230 - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Phase 2/Phase 3
Completed NCT01942135 - Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) Phase 3
Active, not recruiting NCT04448886 - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Phase 2
Completed NCT01401959 - Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy Phase 2
Terminated NCT04720664 - Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer Phase 2
Withdrawn NCT05191004 - Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC Phase 1/Phase 2